| Document |
Document Title |
|
WO/2024/098890A1 |
A pyridone compound and a preparation method therefor, a pharmaceutical composition and a use. The structure of the pyridone compound is as shown in formula (I), and the pyridone compound comprises an isomer, a pharmaceutically acceptabl...
|
|
WO/2024/099404A1 |
The present application relates to a nitrogen-containing spirocyclic compound, a pharmaceutical composition and a use thereof. The nitrogen-containing spirocyclic compound has the structural formula represented by formula (I). The compou...
|
|
WO/2024/098273A1 |
An anti-influenza virus phosphate ester compound and a use thereof. The phosphate ester compound is a compound represented by formula (I) below or a hydrate, a solvate, an optical isomer, a polymorph, an isotope derivative or a pharmaceu...
|
|
WO/2024/099992A1 |
The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4 and R5 are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2024/099440A1 |
A fused ring compound, a use thereof, and a pharmaceutical composition containing same. The compound has a strong inhibitory effect on BRM ATPase, and has a good application prospect in BRG1 gene mutation tumors.
|
|
WO/2024/100093A1 |
The present invention relates to compounds that can specifically activate TLR7. The compounds of the invention are useful because they can stimulate innate immunity. The compounds of the invention can be used in the treatment of conditio...
|
|
WO/2024/099242A1 |
Provided are a deuterated aminopyridine derivative as represented by formula I, an optical isomer or mixture thereof, a polymorph thereof, a salt thereof, or a hydrate or solvate thereof; further provided is a pharmaceutical composition ...
|
|
WO/2024/099438A1 |
Disclosed in the present invention are compounds as SUMO activating enzyme inhibitors. Particularly, the present invention relates to compounds as represented by general formula (1) and general formula (2) and preparation methods therefo...
|
|
WO/2024/098692A1 |
A Wee1 protein kinase degrading agent and a use thereof. Specifically, the compound represented by formula I or a pharmaceutically acceptable salt thereof, and a use thereof in the treatment of proliferative diseases. W-L-D (I).
|
|
WO/2024/102754A2 |
The invention discloses a nitrogen-containing heterocyclic derivative of a somatostatin receptor subtype 4 (SSTR4) small molecule agonist and its pharmaceutical composition, preparation method, and use. The nitrogen-containing heterocycl...
|
|
WO/2024/102621A1 |
Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
|
|
WO/2024/102026A1 |
This invention relates to organic chemistry, pharmacology, medicine, namely the invention relates to compounds for use in inhibiting the activity of human cytochrome 11B2 (CYP11B2) and their use in the treatment and/or prevention of vari...
|
|
WO/2024/099416A1 |
The present invention relates to a fused tricyclic PARP1 inhibitor, a preparation method therefor, and a use thereof. In particular, the present invention relates to a compound capable of inhibiting poly ADP-ribose polymerase activity, a...
|
|
WO/2024/099898A1 |
The invention relates to substituted bi- and tricycles of the general formula (I),and the use of the compounds of the present invention as inhibitorsof HSET for the treatment and/or prevention of hyperproliferative diseases and disorders...
|
|
WO/2024/101336A1 |
One embodiment of the present invention provides a compound, or a pharmaceutically acceptable salt thereof, capable of suppressing the splicing anomalies that are a factor in the onset or progression of disease. This disclosure relates t...
|
|
WO/2024/099437A1 |
Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2024/099135A1 |
Disclosed in the present invention are a compound having a cGAS inhibitory effect or a pharmaceutically acceptable salt thereof, and a use thereof in the preparation of a drug for diseases related to the aberrant expression of cGASs. Spe...
|
|
WO/2024/099441A1 |
Provided are compounds of Formula (A), or pharmaceutically acceptable salts, esters, or prodrugs thereof: T-L-U, wherein T is a BET protein binding moiety (i.e. a ligand for BET proteins), -is a bond, and U is an E3 ubiquitin ligase bind...
|
|
WO/2024/098531A1 |
An intermediate and a use and method of the intermediate in preparation of pyrroloquinoline quinone. The intermediate compound has a structure as shown in formula I or formula II. In the structure, R1 is C1-C3 straight-chain or branched-...
|
|
WO/2024/098530A1 |
The present application provides an intermediate and method for preparing pyrroloquinoline quinone. The method comprises: using a compound of formula (II) as a starting raw material to prepare a compound of formula (III) by means of a Fi...
|
|
WO/2024/102924A1 |
The disclosure provides compounds, in part, compounds of Formula I or Formula II and their use in treating medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and meth...
|
|
WO/2024/101440A1 |
Provided is a compound represented by formula (1): [in the formula, the definitions for variables are as defined in the description] or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/102886A1 |
Disclosed are compounds of Formulas (I): (I) or a salt thereof, wherein R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such comp...
|
|
WO/2024/102447A1 |
This disclosure relates to methods of treating or preventing aneurysms or other vascular diseases of conditions related thereto comprising administering an effective amount of a hydroimidazopyridopyrimidinone derivative or salt thereof t...
|
|
WO/2024/097629A1 |
The present disclosure relates to compounds of Formula (I): or pharmaceutically acceptable salts or isotopically labeled derivatives thereof, wherein A is a 6- to 10- membered bridged bicyclic heterocycloalkyl comprising at least one oxy...
|
|
WO/2024/098001A1 |
The present disclosure relates to compounds (I) and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as mel...
|
|
WO/2024/097296A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/097953A1 |
The present disclosure relates to compounds (I) and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers.
|
|
WO/2024/094163A1 |
Disclosed are a polycyclic ring-fused derivative, a preparation method therefor, and use thereof. In particular, disclosed are a compound represented by general formula (I-2-1), a preparation method therefor, a pharmaceutical composition...
|
|
WO/2024/097575A1 |
Provided are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising c...
|
|
WO/2024/094185A1 |
The present invention belongs to the technical field of medicine, relates to an NLRP3 inflammasome inhibitor and a use thereof, and specifically relates to a compound represented by a general formula (A') or a pharmaceutically acceptable...
|
|
WO/2024/093956A1 |
The present invention relates to the technical field of medicines, in particular to a polycyclic poly(ADP-ribose) polymerase (PARP) selective inhibitor compound as represented by general formula (I), a pharmaceutically acceptable salt th...
|
|
WO/2024/097573A1 |
Provided are compounds of formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising...
|
|
WO/2024/096093A1 |
The present invention provides a compound that has excellent control effects on harmful arthropods. Compounds represented by formula (I) (the meanings of the symbols of which are described in the description) or N-oxides thereof have exc...
|
|
WO/2024/097172A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
|
|
WO/2024/095133A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful a...
|
|
WO/2024/095012A1 |
The invention relates to a compound of formula (Ia) and related aspects.
|
|
WO/2024/097897A1 |
The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/...
|
|
WO/2024/094190A1 |
The present invention relates to use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and/or preventing an inflammatory or immune dis...
|
|
WO/2024/097606A1 |
The present disclosure relates to certain AHR agonist compounds, for example, having a general formula (I) to pharmaceutical compositions comprising the compounds, and to methods of using the compounds to treat immune-mediated diseases, ...
|
|
WO/2024/094963A1 |
Provided are 2-amino-pyrido[2,3-d]pyrimidin-7(8H)-one and 7- amino-l-pyrimido[4,5-d]pyrimidin-2(lH)-one derivatives of the Formula (I), and salts, hydrates and solvates thereof. The compounds are inhibitors of EGFR, including mutated for...
|
|
WO/2024/095172A1 |
The present invention relates to prodrugs of compounds that contain vulnerable amines (e,g, secondary, tertiary and quaternary amines), and methods for their manufacture.
|
|
WO/2024/094181A1 |
The present invention provides a method for preparing finerenone by means of resolving a racemate with a diastereomeric tartaric ester, and also relates to diastereomer salts (VIIa), (VIIb), (VIIc) and/or (VIId). The resolving method use...
|
|
WO/2024/095179A1 |
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, W and m, n, o and p are as defined herein. Use of the compounds as a component o...
|
|
WO/2024/094962A1 |
Provided are pyrido[2,3-d]pyrimidin-2-amine derivatives of the Formula (I), and salts, hydrates and solvates thereof. The compounds are inhibitors of EGFR, including mutated forms of EGFR (for example EGFR comprising a T790M mutation, a ...
|
|
WO/2024/094875A1 |
The present invention relates to compounds, and to associated salts, solvates and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatment and prevention of medical di...
|
|
WO/2024/097576A1 |
Provided are compounds of Formula I, Formula Ib or Formula Ic and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, Formula Ib or ...
|
|
WO/2024/088379A1 |
Disclosed is a tumor treatment or prevention method. The method comprises: administering, to an individual in need of the method, a therapeutically or prophylactically effective amount of a compound represented by general formula (I), or...
|
|
WO/2024/088237A1 |
Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
|
|
WO/2024/089008A1 |
The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
|
